Know Cancer

or
forgot password

Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers


Phase 1
N/A
N/A
Not Enrolling
Both
Colorectal Neoplasm, Hereditary Nonpolyposis

Thank you

Trial Information

Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers


This is a randomized, placebo controlled Phase I/II multi-center trial, of the safety and
efficacy of Celecoxib in a cohort of 81 HNPCC subjects and gene carriers. The three
proposed intervention arms are: Celecoxib (to be provided by Searle) will be administered
at 200 mg p.o. BID x 12 months or 400 mg p.o. BID x 12 months vs. Placebo p.o. BID x 12
months. Assessment of endoscopic and tissue-based biomarker endpoints will be conducted at
baseline and 12 months on study drug or placebo. Patients that present with polyps at
baseline will undergo a month 4 endoscopy. Plasma drug trough samples for pharmacokinetic
analyses will be collected at baseline and month 12. NCI-Chemoprevention Branch will
coordinate the efforts and activities of all sites.

Safety monitoring will occur via in-patient interviews with exams at month twelve; symptom
questionnaires completed at baseline, months one, four, eight and twelve; blood and
urinalysis at baseline and at months one, four, eight and twelve. A post-administration
telephone call to evaluate side effect resolution will occur at months 13-14 for patients
who have unresolved adverse events at the end of month 12.

Inclusion Criteria


Diagnosis of HNPCC patient or HNPCC carrier status defined by:

HNPCC patient is an individual with a personal history of RER plus HNPCC related
malignancy AND; meets the Amsterdam criteria or modified Amsterdam criteria (an HNPCC
associated extracolonic cancer may be substituted for one of the three colorectal cases in
one family otherwise required by these criteria) OR; having a definite mutation of one of
the HNPCC - related genes identified by gene sequencing or other method of reliability.
This includes gene status determined through segregation analysis in cases in which
"direct" testing yields no alteration.

HNPCC carrier is a relative of an individual meeting the criteria of an "HNPCC patient" as
described above and having a mutation of one of the HNPCC-related genes identified by gene
sequencing or other method of equivalent reliability (this includes gene status determined
through segregation analysis in cases in which direct testing yields no alterations, as
above) OR; having an RER plus adenoma.

Age greater than or equal to 18 years.

Voluntary consent documented by a signed and witnessed informed consent.

Willingness to abstain from use of NSAID's (including aspirin), oral
adrenocorticosteroids, and other nonsterodial OTC products for the duration of the study.

If patient is female and of childbearing potential, she must meet all of the following
conditions:

Have been using adequate contraception (e.g., abstinence, condom, IUD, birth control pill,
diaphragm and spermicide gel combination) since her last menses AND;

Be willing to use adequate contraception (as above) during the study AND;

Not be breastfeeding AND;

Have a negative serum pregnancy test within 14 days prior to study drug administration.

Though an individual with prior colorectal surgery is allowed, the subject must have
greater than or equal to 50 percent of the colorectum with documentation describing the
post-surgical anatomy (e.g., operative report).

No use of investigational agent within the last 3 months, or at the discretion of the
medical monitor.

The subject will be allowed to proceed to baseline colonoscopy so long as all of the
following laboratory criteria are met on baseline evaluation: Hgb greater than 10.0
gm/dl, platelet count greater than 100,000/ul; WBC greater than 3,000/ul; ALT less than
1.5 x upper limit of normal; AST less than 1.5 x upper limit of normal, alkaline
phosphatase less than 1.5 x upper limit of normal, total bilirubin less than 1.2 x upper
limit of normal, creatinine less than 1.5 x upper limit of normal, negative pregnancy
test. For tests not mentioned specifically, there must be no clinically significant
abnormalities which in the opinion of the PI would preclude a subject's safe
participation.

To proceed to randomization, the subject must have all of the following:

An assessable colon or colonic segment (greater than or equal to 50 percent) which was
endoscopically evaluated in its entirety following an adequate preparative procedure AND;

An assessment of aberrant crypt foci via "enhanced" endoscopy 10 cm distal to the
ileocecal valve or 10 cm distal to the anastamosis and at the distal most 10 cm from the
rectum AND;

All polyps must have been removed with the exception of small polyps (less than or equal
to 0.6 cm in maximal diameter) amenable to serial endoscopic surveillance AND;

Mucosal sampling via pinch biopsies must have been obtained from normal-appearing mucosa
in standardized areas of the right and left colon (or surrogate regions in the case of
prior surgical resections) and from any areas that are clearly neoplastic or suspicious
for neoplastic pathologies (ACF, adenomas, carcinomas) of interest.

No anticipated colectomy within eighteen months of randomization.

No history of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAID's or salicylates.

No use of NSAID's (including aspirin) or oral adrenocorticosteroids, at any dose at a
frequency averaging greater than 3 times per week during the six months prior to study
entry. Use of such NSAID's or oral adrenocorticosteroids at the above frequency will
require a six-month washout period prior to eligibility, beginning with the time of the
patient's last dose. Use of any dose of NSAID's or oral adrenocorticosteroids, at an
average frequency of 1-3 times per week during the six months prior to study entry will
require a three-month washout period beginning with the time of last dose.

No history in the past year of discrete gastric or duodenal ulcer of size greater than 5
mm, except that patients with a history of Helicobacter pylori-related peptic ulcer
disease may become eligible for study upon successfully completing antibiotic treatment of
Helicobacter pylori.

Ability to participate in the scheduled follow-up tests.

No significant medical or psychiatric problems which would make the patient a poor
protocol candidate, in the opinion of the principal investigator.

No "unacceptable clinical risk" to proceed (based upon the subclinical discoveries made
via baseline colonoscopy and biopsies) including a previously-unknown bleeding diathesis,
a new diagnosis of carcinoma, suspicion that the subject may require colectomy (complete
or partial) within eighteen months of randomization.

Patient must not have undergone a colectomy within the past 6 months.

Patient must not have undergone chemotherapy within the past 6 months.

Patient must not have received pelvic radiation.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Primary Purpose: Treatment

Authority:

United States: Federal Government

Study ID:

980087

NCT ID:

NCT00001693

Start Date:

March 1998

Completion Date:

January 2002

Related Keywords:

  • Colorectal Neoplasm
  • Hereditary Nonpolyposis
  • Chemoprevention
  • Biomarkers
  • Endoscopy
  • Colorectal
  • Celecoxib
  • Neoplasms
  • Colorectal Neoplasms
  • Colorectal Neoplasms, Hereditary Nonpolyposis

Name

Location

National Cancer Institute (NCI)Bethesda, Maryland  20892